GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Net Income Including Noncontrolling Interests

Firebrick Pharma (ASX:FRE) Net Income Including Noncontrolling Interests : A$-1.72 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Firebrick Pharma's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2024 was A$-1.45 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 was A$-1.72 Mil.

Firebrick Pharma Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Firebrick Pharma's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Net Income Including Noncontrolling Interests Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Net Income Including Noncontrolling Interests
- -3.80 -6.80 -1.18

Firebrick Pharma Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial -3.13 -3.67 -0.90 -0.28 -1.45

Firebrick Pharma Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-1.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Firebrick Pharma Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
ASX:ECS ASX:PER ASX:IVX ASX:EOF ASX:AGH ASX:NXS ASX:CAN ASX:RGT ASX:EXL ASX:BP8 LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN GILD
Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Website
https://www.firebrickpharma.com
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines